Allergan, Argentum Settle Patent Dispute Over Restasis

Source: Reuters

Wednesday, April 19, 2017 | Corporate Lawsuits , Allergan

U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis. The agreement gives Argentum the right to sell the copycat version of Restasis before the patents covering the drug expire, Argentum said. It did not disclose when it would launch the generic product.


Open in New Window


You must be logged in to leave a comment.